The Vancouver-based biotech company has a product pipeline that includes IMS-088, a small-molecule compound designed to address immune system activation pathway involved in neurodegeneration, as well as TDP-43 Associated NF-kB Activation Inhibitors. Their therapies are also used for the treatment of Alzheimer's, Parkinson's disease, and dementia, with the aim of curing diseases more efficiently. ImStar Therapeutics takes a breakthrough approach to treating ALS and related neurodegenerative disorders by exploiting a new biological target underlying the disease.